drugset / Trial / NCT04343248

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

NCT04343248

Phase 3 Terminated 190 enrolled Romark Laboratories L.C.
RandomizedParallel-groupTriple-blindPrevention

Summary

Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.

Timeline

Start
2020-05-12
Primary completion
2021-02-01
Completion
2021-02-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitazoxanide Other / unclassified 600 mg Oral